WASHINGTON -- Treatment with the investigational GLP-1/glucagon dual receptor agonist pemvidutide led to resolution of ...

CNBC's Bertha Coombs asks President Trump and his team at the White House's announcement on lower prices for Eli Lilly and ...

Drugs like Ozempic, known collectively as GLP-1 receptor agonists, have become more widely used in recent years. Though they ...

As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo ...

Insurance data reveals dramatic regional differences in Ozempic and Mounjaro usage, with obesity-heavy states prescribing GLP ...

For long-term investors, there are plenty of reasons to buy and hold Eli Lilly for not only years but decades.

ATLANTA -- Women who had been taking GLP-1 receptor agonist medications prior to becoming pregnant had a lower risk of ...

At a time when insurers are backing away from coverage for weight loss medications, President Trump has offered a lifeline ...

Eli Lilly's Mounjaro and Zepbound deliver accelerated weight loss rates compared to Novo Nordisk's Wegovy. Learn why LLY ...

President Trump's plan drops the price of Ozempic and Wegovy for Americans, with plans for Medicare to cover the popular ...

A new University of California San Diego study offers compelling evidence that glucagon-like peptide-1 (GLP-1) receptor ...

President Trump has announced a deal to lower the cost of weight-loss drugs Wegovy and Zepbound, with coverage of the drugs ...